Easing the Burden of Moderate-to-Severe Atopic Dermatitis: Assessing Severity, Targeting Pathways, and Improving Quality of Life

Easing the Burden of Moderate-to-Severe Atopic Dermatitis: Assessing Severity, Targeting Pathways, and Improving Quality of Life

Released: 12/22/2020
Expires: 12/21/2021
Max Credits: 1.0
Jump to Education

Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL

Elaine C. Siegfried, MD
Professor of Pediatrics and Dermatology
Director, Division of Pediatric Dermatology
Department of Pediatrics
Saint Louis University School of Medicine
Cardinal Glennon Children’s Hospital
St. Louis, MO

Activity Planners
Susan Kuhn, MHSc
Manager, Educational Strategy and Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Consider clinical, functional, psychosocial/mental health, and quality-of-life factors when assessing AD severity and potential treatment changes
  • Identify key inflammatory cytokines and signaling pathways that contribute to the pathogenesis of moderate-to-severe AD
  • Integrate recent clinical data on current and emerging targeted therapies into personalized treatment plans for moderate-to-severe AD

Target Audience
This activity is intended for primary care physicians, dermatologists, allergists, pediatric dermatologists, and nurse practitioners and physician assistants in dermatology and primary care.

Statement of Need
Atopic dermatitis (AD) is a common inflammatory disorder driven by skin barrier disruptions and immune system dysregulation. Moderate-to-severe disease is present in as many as one-third of patients with AD and is associated with markedly reduced quality of life and overall well-being. Patients with uncontrolled moderate-to-severe AD have a major unmet treatment need, with frequent cycles of flares and periods of remission. Conventional therapies, including topical agents, have demonstrated efficacy. In addition, the approval of an effective targeted systemic therapy has led to improvements in control of moderate-to-severe AD, as well as other atopic diseases that share commonality along the IL-4 and IL-13 pathway, which are primary drivers of the inflammatory response in AD. With emerging knowledge on the histologic and inflammatory properties of nonlesional skin and the prospect of additional targeted therapies for both adult and pediatric patients with moderate-to-severe AD, there is an immediate educational gap for dermatologists and primary care clinicians who manage patients with this chronic and often debilitating condition.

Collaboration Statement
Med-IQ        National Eczema Association

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 1.0 contact hour.

CME MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
To receive credit, read the introductory CME/CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: December 22, 2020
Expiration Date: December 21, 2021
Estimated Time to Complete This Activity: 60 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Peter A. Lio, MD
Royalty: Theraplex
Consulting fees/advisory boards: AbbVie Inc., Altus Labs, Amyris, Inc., Arbonne, Bodewell, Burt's Bees, Dermavant Sciences, Dermira, Dermveda, Eli Lilly and Company, Exeltis, Franklin BioScience, gpower, inc., IntraDerm Pharmaceuticals, Johnson & Johnson, Kiniksa Pharmaceuticals, LEO Pharma, Inc., L'Oreal USA Inc., Menlo Therapeutics, Micreos Human Health B.V., Realm Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., Syncere Skin Systems, Theraplex, TopMD, UCS, Unilever, Verrica Pharmaceuticals, YobeeCare Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Altus Labs, DermTap, Inc., Dermveda, Franklin BioScience, LearnHealth/LearnSkin, Medable, Micreos Human Health B.V., Modernizing Medicine, Odeza LLC, Syncere Skin Systems
Speaker/Investigator: AbbVie Inc., AOBiome, LLC, Dermatologie, La Fondation pour la Dermatite Atopique, La Roche-Posay Laboratorie Pharmaceutique, Pfizer, Inc., Pierre Fabre, Regeneron Pharmaceuticals, Inc.

Elaine C. Siegfried, MD
Consulting fees/advisory boards: AbbVie Inc., Boehringer Inglheim Pharmaceuticals, Inc., Incyte Corporation, LEO Pharma, Inc., Novartis Pharmaceuticals Corporation, Noven Pharmaceuticals, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., UCB, Inc., Verrica Pharmaceuticals
Fees received for promotional/non-CME activities: Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: AI Therapeutics

Susan Kuhn, MHSc
Spouse Ownership interest (stocks/stock options – excluding mutual funds): Illumina, Johnson & Johnson, Viking Therapeutics

The peer reviewers and other activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For CME/CE questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

© 2020 Med-IQ, Inc.


Here are some key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available by clicking the "Continue" button below.

Welcome to this Med-IQ webcast on easing the burden of moderate-to-severe atopic dermatitis (AD). Informed by a large patient and caregiver survey administered via social media, this activity focuses on the effects of moderate-to-severe AD on individuals and their families. It also provides clinicians with strategies to assess and treat patients with this condition, discuss available treatment options, and ultimately improve patient quality of life. Key clinical takeaways from this activity include:

  • Moderate-to-severe disease is present in as many as one-third of patients with AD and is associated with markedly reduced quality of life and overall well-being
  • Survey data reveal that patients’ perceptions of their AD and its effects on their daily lives (beyond clinical presentation) often do not align with their providers’ assessments
  • Some survey highlights include:
    • Most patients with AD are not being seen by a dermatologist or pediatric dermatologist, even if they have more severe disease
    • More than one-half of respondents report that their or their child’s AD is not well controlled
    • Most patients or their caregivers report not having completed assessment questionnaires, nor have they received an eczema action plan
    • Most patients or caregivers report not being fully informed of their treatment options or the risks and benefits associated with available therapies
  • Evaluation should include identification of moderate-to-severe AD and coexisting atopic conditions and should incorporate the use of validated clinician-based assessment tools, patient-reported tools, and mental health assessment
  • Effective options that target AD pathways that play a role in acute and chronic lesion formation are available for moderate-to-severe AD; the pipeline of new treatments is robust
  • Patient-provider discussions and patient education are key to achieving successful management, and treatment should be tailored based on individual patient needs and preferences
  • Patients with insufficiently controlled AD require consultation with or referral to an eczema specialist for consideration of advanced care and treatment

Click "Continue" to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the chapters in this activity.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.